Merck Serono enters antibody drug conjugate fray

Merck Serono has expanded its oncology activities into antibody drug conjugates (ADCs) through a deal signed with Cambridge, Massachusetts-based Mersana Therapeutics.

Merck Serono has expanded its oncology activities into antibody drug conjugates (ADCs) through a deal signed with Cambridge, Massachusetts-based Mersana Therapeutics.

The companies will research the use of Mersana's Fleximer technology to attach a range of cytotoxic agents to monoclonal antibodies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category